preview

The Food And Drug Administration

Better Essays

In 2008, the Food and Drug Administration (FDA) approved the use of Moxatag, a once daily extended release formulation of amoxicillin, for the treatment of streptococcal pharyngitis. The clinical study results indicated that Moxatag was as safe and effective as penicillin V, the first drug of choice for the treatment of pharyngitis (Infectious Disease Society of America, 2013). Moxatag is the only once daily medication FDA approved for the treatment of pharyngitis. The manufacturer claims that once daily dosing will improve compliance, thus improving patient outcomes. Moxatag is very expensive relative to immediate release penicillin. Price comparisons found a difference of 144 dollars between Moxatag and the next equivalent medication. There are equivalent alternative medications, although these medications have their own drawbacks, being off label, intramuscular injectable or increased doses per day. Also, on August 25, 2014 it was announced that a generic for Moxatag is being produced (Fera, 2014), which will introduce a lower cost once daily alternative. Once this medication is introduced, it may offer a better option than the current alternatives to Moxatag. For the time being, however, I believe that with good prescribing practices, these current alternatives are effective and significantly less expensive, which make Moxatag unnecessary to prescribe.

Marketing and Research of Pharmaceuticals: Moxatag tablet
In this paper I will review the indications for

Get Access